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ification. We analysed data of pregnant women aged 18-50 years for whom the following diagnoses were
recorded during hospitalization: (i) pulmonary embolism (I26) during pregnancy or peripartum (O09) or
(ii) obstetric thromboembolism (O88.2). Haemodynamic failure at any time during the in-hospital stay
was defined as need for cardiopulmonary resuscitation (OPS code 8-77) or the presence of shock (Interna-
tional Classification of Diseases and Related Health Problems, 10th Revision with German Modification
code R57). The primary study outcome was in-hospital death. A total of 8 271 327 births were registered
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Abstract
Aims Data on the early course and use of systemic thrombolysis in pregnant women with pulmonary embolism associated or
not with haemodynamic failure are scarce. We investigated these aspects using the information from the German Nationwide
Inpatient Registry (years 2005–2016).
Methods and results In Germany, all diagnoses referring to hospitalized patients are coded according to the International
Classification of Diseases and Related Health Problems, 10th Revision with German Modification. We analysed data of preg-
nant women aged 18–50 years for whom the following diagnoses were recorded during hospitalization: (i) pulmonary embo-
lism (I26) during pregnancy or peripartum (O09) or (ii) obstetric thromboembolism (O88.2). Haemodynamic failure at any time
during the in-hospital stay was defined as need for cardiopulmonary resuscitation (OPS code 8-77) or the presence of shock
(International Classification of Diseases and Related Health Problems, 10th Revision with German Modification code R57).
The primary study outcome was in-hospital death. A total of 8 271 327 births were registered in Germany from 2005 to
2016. During this 12 year time period, there were 1846 hospitalizations for pregnancy-associated pulmonary embolism in pa-
tients aged 18–50, corresponding to 2.2 [95% confidence interval (CI): 2.1–2.3] cases every 10 000 births and 0.2% of all hos-
pitalizations for pulmonary embolism in Germany. The median age was 31 years, and the median length of hospitalization was
8 days. A total of 63 deaths were reported, corresponding to an overall in-hospital fatality rate of 3.4% (95% CI: 2.7–4.4) and a
pulmonary embolism-related mortality rate of 0.8 (95% CI: 0.6–1.0) per 100 000 (live) births per year. Pulmonary
embolism-related deaths in hospitalized pregnant women represented 14% of all maternal deaths recorded in Germany be-
tween 2005 and 2016. A total of 135 (7.3%) women had haemodynamic failure, of whom 51 (37.8%) received systemic throm-
bolysis and 50 (37.0%) died.
Conclusions Pulmonary embolism-related fatality remains substantial in pregnant women with pulmonary embolism and
represents a frequent cause of maternal mortality. The use of systemic thrombolysis was reported in one third of pregnant
women with pulmonary embolism and haemodynamic failure. Better preventive and management strategies should be ur-
gently implemented in this vulnerable patient group.
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Introduction
Acute venous thromboembolism complicates one in 500–
3000 pregnancies1–3 and represents a leading cause of death
among younger women in Western countries.4–7 A recent
analysis of medically certified vital registration data in
Europe demonstrated that, despite an overall decreasing
trend in age-standardized pulmonary embolism-related
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mortality, more than 1% of all deaths in younger women are
due to pulmonary embolism.8 This figure is almost two times
higher than that observed in men of the same age.8
While the mainstay of therapy for acute pulmonary embo-
lism is anticoagulation, systemic thrombolysis is recom-
mended to rapidly relieve the right ventricle and reduce
fatality in patients who present with haemodynamic instabil-
ity, which comprise up to 10% of all cases and have a
fatality of up to 68% in the first 5 days of hospitalization.9,10
Other reperfusion options, including surgical embolectomy
or catheter-directed treatment, are less frequently used ther-
apeutic alternatives, depending on the patient’s profile and
the expertise available at a given centre. However, systemic
thrombolysis is probably underused. It has been recently re-
ported that it is used in only 26% of haemodynamically unsta-
ble patients with acute pulmonary embolism in Germany.11
The management of acute pulmonary embolism during
pregnancy is challenging. First, pregnancy has been associ-
ated with improper diagnostic management of suspected pul-
monary embolism because validated diagnostic algorithms
were unavailable until recently,12,13 and concerns on the po-
tential harm of radiation or iodine contrast exposure fuel
an ongoing debate on the best imaging modality.14,15 Inter-
ventional studies for treatment of pregnancy associated pul-
monary embolism are not available.10,16 The evidence on
the role of reperfusion strategies during pregnancy is limited
too: its use for high-risk pulmonary embolism during preg-
nancy is therefore only supported by a low level of
recommendation.9,10 A recent systematic review of the
literature identified a limited number of 83 published cases
and showed that pregnant women with high-risk or
intermediate-risk pulmonary embolism had a high survival
rate (94%) after systemic thrombolysis, although major ma-
ternal bleeding was observed in 28.4% of women.17
In the present study, we investigated the case fatality and
the use of systemic thrombolysis for acute pulmonary embo-
lism in pregnant women with and without haemodynamic
failure included in the German Nationwide Inpatient Registry
from 2005 to 2016.
Methods
Diagnoses, procedural codes, and definitions
In Germany, all diagnoses referring to hospitalized patients
are coded according to the International Classification of
Diseases and Related Health Problems, 10th Revision with
German Modification (ICD-10-GM) and included in a
Nationwide Inpatient Registry. Diagnostic, general medical,
and surgical invasive procedures are classified according to
the German Procedure Classification [Operationen-
und Prozedurenschlüssel (OPS), surgery and procedures
codes]. The data of hospitalized patients with their
Diagnosis-Related Group (DRG) are collected and managed by
the Federal Statistical Office of Germany.11 This DRG system,
which had been introduced in 2003–2004, applies to all hospi-
tals, departments, and patients with the exclusion of rehabilita-
tion and psychiatric institutions. The coding quality of German
DRG data is routinely monitored by the regional medical review
boards of the sickness funds, which verify the assignment of in-
dividual cases and corresponding resource utilization across ran-
domly selected institutions (12% of all in-hospital cases were
monitored in 2009). Hospitals that intentionally up-coded cases
to increase their DRG-based reimbursement would receive noti-
fication for a penalty payment. Further details concerning these
procedures have been summarized by the European Observa-
tory on Health Systems and Policies.18,19
Study population and definition of pulmonary
embolism and clinical variables
The ICD-10-GM code O09 for pregnancy and peripartum
served for the identification of pregnant women up to 41
gestational weeks hospitalized with a primary diagnosis of
pulmonary embolism (code I26) from 2005 to 2016. Alterna-
tively, the code O88.2 for obstetric thromboembolism was
used to identify women with pregnancy-associated pulmo-
nary embolism. The analysis was restricted to women aged
18–50 years at delivery who were treated with anticoagulant
therapy or with systemic thrombolysis (source: RDC of the
Federal Statistical Office and the Statistical Offices of the fed-
eral states, DRG Statistics 2005-2016, and own calculations).
Haemodynamic failure at any time during the in-hospital stay
was defined as need for cardiopulmonary resuscitation (OPS
code 8-77) or the presence of shock (ICD-10-GM code R57).
For subgroup analysis, patients with haemodynamic failure were
further stratified into (i) patients who required cardiopulmonary
resuscitation and (ii) patients with haemodynamic failure but re-
quiring neither cardiopulmonary resuscitation nor mechanical
ventilation (OPS codes 8-70 and 8-71).
The use of systemic thrombolysis was based on the OPS
code 8-020.8. We excluded patients for whom the following
OPS codes were reported: 8-838.d0 (percutaneous rotational
pulmonary embolectomy), 8-838.70 (percutaneous pulmo-
nary embolus defragmentation), 8-838.50 (or percutaneous
pulmonary embolus aspiration), and catheter-directed treat-
ment (OPS 8-83860 and OPS 8-83bj). The following variables
were also captured: pre-eclampsia (O14), eclampsia (O15),
cancer not including pregnancy-related malignant neoplasms
(ICD-10-GM codes C00-C97), heart failure (ICD-10-GM code
I50), obesity (ICD-10-GM code E66), deep vein thrombosis
or thrombophlebitis of the leg veins (ICD-10-GM codes I80)
transfusion of erythrocyte concentrates (OPS code 8-800)
and surgery during in-hospital stay (OPS code 5). Information
on pulmonary embolism occurring during post-partum could
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not be extracted because no specific code allows unique iden-
tification of this period.
Because this study did not involve direct access to data
of individual patients by the investigators, approval by an
Ethics Committee and informed consent were not required,
in accordance with German regulations. We could not
obtain information on specific conditions and outcomes ob-
served in five or fewer patients for each subgroup, which
were censored by the Federal Statistical Office and the Statis-
tical Offices of the federal states to prevent potential
re-identification of patients.
Study outcomes
The primary outcome is all-cause in-hospital death.
Statistical methods
Continuous variables are presented as median and interquar-
tile range or mean and standard deviation, depending on
their distribution. Categorical variables are provided as
counts and percentages. Total numbers of pulmonary embo-
lism cases, incidence, in-hospital death rate, and length of
in-hospital stay were calculated for each calendar year. Crude
fatality rates by dividing the number of deaths by pulmonary
embolism by the number of pregnancy-associated diagnoses
of pulmonary embolism recorded in the Nationwide Inpatient
Registry; their confidence interval (CI) was calculated using
the Wilson score formula. We used smoothed lines generated
by locally estimated scatterplot smoothing with least
squares fitting to depict the trends in the incidence and crude
fatality rate of pulmonary embolism over the study period.
Univariable and multivariable (age-adjusted) logistic regres-
sion models explored the association between systemic
thrombolysis and fatality in patients who developed haemo-
dynamic failure during hospitalization.
Crude incidence rates were estimated by dividing the
number of pregnancy-associated diagnoses of pulmonary
embolism by the number of live births. For calculation
of the annual incidence rates of pulmonary embolism
among pregnant women and death rates related to
pregnancy-associated pulmonary embolism, the number of
all births in Germany in the same year was used as denomina-
tor, as provided by the Federal Statistical Office of Germany.
Because we did not anticipate major differences in the
distribution of pregnancies across the 5year age groups
during the period 2005–2016, no age-standardization of rates
was performed.
We estimated the proportionate mortality (95% CI) for pul-
monary embolism, calculated as the number of pulmonary
embolism-related deaths registered in the Nationwide Inpa-
tient Registry database of the total number of maternal
deaths reported in the Global Health Observatory data repos-
itory of the World Health Organization (available at apps.
who.int and data.worldbank.org).
The statistical analyses were run on behalf of the investiga-
tors by the Research Data Center of the Federal Statistical
Office and the Statistical Offices of the federal states in Wies-
baden, Germany, who provided the results as aggregated
data. SPSS® (version 20.0, Chicago, Illinois, USA) served for
data analysis. The figures and the CIs of incidence, mortality,
and case fatality rates were obtained by the investigators
using R (version 3.5.3, package epitools).
Role of the funding source
The funder of the study (German Federal Ministry of Educa-
tion and Research) had no role in study design, data
FIGURE 1 Incidence and case fatality of pregnancy-associated pulmonary
embolism in Germany, 2005–2016. CI, confidence interval.
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collection, data analysis, data interpretation, or writing of the
report. The corresponding author had full access to all the
data in the study and had final responsibility for the decision
to submit for publication.
Results
A total of 8 362 030 births were registered in Germany
from 2005 to 2016, including 30 131 stillbirths. During this
12 year time period, there were 1846 hospitalizations for
pregnancy-associated pulmonary embolism in patients aged
18–50 years, corresponding to 2.2 (95% CI: 2.1–2.3) cases ev-
ery 10 000 births/live births in women of the same age
and 0.2% of all hospitalizations for pulmonary embolism in
Germany. The annual rate of pulmonary embolism among
pregnant women over time is depicted in Figure 1. A total
of 1839 patients were included in the present analysis after
exclusion of six women who underwent pulmonary endarter-
ectomy and one treated with catheter-directed reperfusion
therapy.
Patient risk profile and clinical characteristics
Table 1 summarizes the baseline characteristics of pregnant
women hospitalized for acute pulmonary embolism. The median
age was 31 years, and the median length of hospitalization was
8 days. The majority of the cases of pulmonary embolism
(n = 946; 51.4%) were diagnosed between the 34th and the
41th week of gestation. A code for haemodynamic failure or
cardiopulmonary resuscitation was assigned to a total of 135
(7.3%) women, who were classified as haemodynamically
unstable for the purposes of the present analysis. Differences
in demographic and baseline characteristics between patients
with versus without haemodynamic instability are summarized
in Table 1.
Pulmonary embolism-related fatality and death
rate
A total of 63 deaths were reported in pregnant women hos-
pitalized for acute pulmonary embolism from 2005 to 2016,
corresponding to an in-hospital case fatality rate of 3.4%
(95% CI: 2.7–4.4). Using as denominator the number of
(live) births reported by the Federal Statistical Office of
Germany during the same time period, we estimated an aver-
age pulmonary embolism-related mortality rate of 0.8 (95%
CI: 0.6–1.0) per 100 000 (live) births per year. The estimated
proportionate mortality for pregnancy-associated pulmonary
embolism was 13.7% (95% CI: 10.9–17.1), corresponding to
the number of deaths in women hospitalized for pulmonary
embolism out of all maternal deaths (N = 460) reported in
Germany from 2005 to 2016.














Age (years) 31 (27–35) 33 (30–37) 31 (26–35) —
In-hospital stay (days) 8 (4–14) 10 (2–19) 8 (5–14) —
Duration of pregnancy
<5 weeks 11 (0.6%) 0 (0.0%) 11 (0.6%) +0.0% (4.5%; +6.6%)
5–13 weeks 193 (10.5%) 15 (11.1%) 178 (10.4%)
14–19 weeks 60 (3.3%) 3 (2.2%) 57 (3.3%) +0.2% (4.5%; +6.9%)
20–25 weeks 155 (8.4%) 13 (9.6%) 142 (8.3%)
26–33 weeks 407 (22.1%) 18 (13.3%) 389 (22.8%) 13.8% (20.4%; 5.9%)
34–36 weeks 224 (12.2%) 11 (8.1%) 213 (12.5%)
37–41 weeks
b
722 (39.3%) 67 (49.6%) 655 (38.4%) +11.2% (+2.6%; +19.8%)
Clinical presentation, co-morbidities, and provoking risk factors
Surgery during the
in-hospital stay
1251 (68.0%) 119 (88.1%) 1132 (66.4%) +21.7% (+14.8%; +26.7%)
Obesity 104 (5.7%) 10 (7.4%) 94 (5.5%) +1.9% (1.6%; +7.7%)
Heart failure 80 (4.4%) 19 (14.1%) 61 (3.6%) +10.5% (+5.5%; +17.4%)
Deep venous thrombosis
or thrombophlebitis
109 (5.9%) 10 (9.2%) 99 (5.8%) +1.6% (2.0%; +7.4%)
Preeclampsia 139 (7.6%) 10 (7.4%) 129 (7.6%) 0.16% (3.8%; +5.6%)
Eclampsia 17 (0.8%) 3 (2.2%) 14 (0.8%) +1.4% (0.2%; +5.5%)
HELLP syndrome 30 (1.6%) 3 (2.2%) 27 (1.6%) +0.6% (1.0%; +4.8%)
In-hospital stay (days) 8 (4–14) 10 (2–19) 8 (5–14) —
Systemic thrombolysis 67 (3.6%) 51 (37.8%) 16 (0.9%) +36.8% (+29.1%; +45.3%)
In-hospital cumulative death rate 63 (3.4%) 50 (37.0%) 13 (0.8%) +36.3% (+28.6%; +44.7%)
a
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Of the 63 deaths, 50 occurred among patients with haemo-
dynamic failure (case fatality rate 37.0% in this subgroup) and
13 among patients without haemodynamic failure (case fatal-
ity rate 0.8%) for an absolute risk difference of +36.3% (95%
CI: +28.6% to +44.7%).
Use of systemic thrombolysis
Systemic thrombolysis was administered to 67 (3.6%) of 1839
pregnant women with pulmonary embolism and to 51
(37.8%) of the 135 patients with haemodynamic failure. Sys-
temic thrombolysis was more frequent applied during the
first 13 weeks of pregnancy and between weeks 37 and 41
(Supporting Information, Table S1). The proportions of pa-
tients with haemodynamic failure among all cases of
pregnancy-related pulmonary embolism and that of patients
receiving systemic thrombolysis are depicted in Figure 2.
Among women with pulmonary embolism and haemody-
namic failure, the odds of death was higher among patients
receiving systemic thrombolysis [crude odds ratio 3.43 (95%
CI: 1.64–7.16); age-adjusted odds ratio 3.48 (95% CI: 1.66–
7.27)].
The distribution of co-morbidities between patients who
underwent (versus those who did not undergo) systemic
thrombolysis tended to parallel that presented in Table 1
for patients stratified by the presence of haemodynamic fail-
ure. A total of five intracerebral bleeding events were re-
corded, but we were unable to determine whether they
occurred in women who received systemic thrombolysis to
prevent potential re-identification of patients.
Discussion
Comprehensive analyses of the rate of occurrence and early
outcome of acute pregnancy-associated pulmonary embolism
are not available to this date, particularly with regard the use
of systemic thrombolysis. Our nationwide analysis, covering a
12 year period and based on administrative data of more
than 1800 women with pregnancy-associated pulmonary em-
bolism in Germany, provides nationwide estimates of case fa-
tality and the use of systemic thrombolysis in this population
(Table 2).
FIGURE 2 Proportion of pregnant women with pulmonary embolism and
haemodynamic failure (high risk) and use of systemic thrombolysis in
Germany from 2005 to 2016.
Table 2 Baseline characteristics of 1839 pregnant women with pulmonary embolism stratified by systemic lysis treatment
Parameters




(n = 67; 3.6%)
No thrombolysis
(n = 1771; 96.3%)
Absolute risk difference
(95% CI)
Age (years) 31 (27–35) 32 (29–36) 31 (27–35) —
Obesity 104 (5.7%) 6 (8.8%) 98 (5.5%) +3.3% (1.6%; +12.5%)
In-hospital stay (days) 8 (4–14) 9 (2–20) 8 (4–14) —
Pregnancy <5 weeks 11 (0.6%) 0 (0.0%) 11 (0.6%) +8.3% (+0.6%; +19.3%)
Pregnancy 5–13 weeks 193 (10.5%) 13 (19.1%) 180 (10.2%)
Pregnancy 14–19 weeks 60 (3.3%) Censored Censored 1.1% (5.5%; +7.7%)
Pregnancy 20–25 weeks 155 (8.4%) 5 (7.4%) 150 (8.5%)
Pregnancy 26–33 weeks 407 (22.1%) 9 (13.2%) 398 (22.5%) 17.3% (24.9%; 6.4%)
Pregnancy 34–36 weeks 224 (12.2%) 3 (4.4%) 221 (12.5%)




1251 (68.0%) 53 (77.9%) 1198 (67.6%) +10.3% (1.10; +18.8%)
Heart failure 80 (4.4%) 9 (13.2%) 71 (4.0%) +9.2% (+3.0%; +19.3%)
Deep venous thrombosis or
thrombophlebitis
109 (5.9%) 6 (8.8%) 103 (5.8%) +3.0% (1.9%; +12.2%)
Haemodynamic failure 135 (7.3%) 52 (76.5%) 83 (4.7%) +71.8% (+60.4%; +80.3%)
Mechanical ventilation 175 (9.5%) 40 (58.8%) 135 (7.6%) +51.2% (+39.3%; +62.2%)
Outcome
In-hospital mortality 63 (3.4%) 29 (42.6%) 34 (1.9%) +40.7% (+29.7%; +52.6%)
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We found that the in-hospital fatality rate in women hospi-
talized for pulmonary embolism is substantial (3.4 deaths per
100 pregnant women with a diagnosis of pulmonary embo-
lism) and approximately 500 times higher than the maternal
mortality in Germany during the same time period (five to
six deaths per 100 000 live births) excluding pulmonary
embolism.20 Deaths during hospitalizations for pulmonary
embolism in pregnant women accounted for almost 14% of
all maternal deaths. In particular, pregnant women with pul-
monary embolism and haemodynamic failure were character-
ized by very high death rates, with more than one third of
these patients dying during hospitalization as compared with
less than 1% in women without haemodynamic failure. This
observation could partly explain why pulmonary embolism
represented a much more frequent cause of death among
younger women aged 15–55 years than in men of the same
age.8 While these estimates concerning the overall fatality
rates are similar to what described in prior studies,21 the
in-hospital fatality rate among women with pulmonary embo-
lism and haemodynamic failure (37%) depicts a much more
pessimistic picture than that derived from small case series
and reports (7.6% in high-risk or intermediate-risk patients).17
Fatality estimates obtained from case reports were even
lower (approximately 5%) if only antenatal pulmonary embo-
lism were considered.17
We showed that use of systemic thrombolysis was rarely
recorded among pregnant women, even in the presence of
haemodynamic failure; in fact, the code for the use of lytic
therapy was reported in only one third of women with pul-
monary embolism and haemodynamic failure. The fact that
the death rate was higher among those women who received
systemic thrombolysis most likely suggests that this treat-
ment was used as a last resort option in the most severely
compromised patients. Of note, the observational nature of
our data prevents us from drawing any conclusions
concerning the efficacy and safety of systemic thrombolysis
during pregnancy. A prospective registry endorsed by the In-
ternational Society on Thrombosis and Haemostasis will set
out to investigate the course of high-risk pulmonary embo-
lism among pregnant women receiving systemic or
catheter-directed thrombolysis.22
Our results are consistent with prior epidemiological stud-
ies estimating the incidence of pulmonary embolism during
pregnancy.4,5,7,23 In particular, we found that pulmonary em-
bolism was recorded as a complication in an average of one
every 4000 pregnancies in Germany between 2005 and
2007, decreasing to approximately one per 5000 between
2014 and 2016. The observed incidence of 25 cases of pulmo-
nary embolism per 100 000 pregnancies in Germany in 2005
is consistent with the estimates obtained in Canada (26 per
100 000 pregnancies in 2004–2005),24 United Kingdom (13
per 100 000 in 2005–2006),21 and Scotland (30 per 100 000
pregnancies in 2001–2005).25 In our study, the majority of
events occurred after week 34 of gestation and a number
of co-morbidities were more prevalent in women with pul-
monary embolism associated with haemodynamic failure or
requiring cardiopulmonary resuscitation, including caesarean
section, obesity, and heart failure. Caesarean section and
the latter co-morbidities have been previously identified as
key risk factors for the development of pulmonary embolism
among pregnant women26 but not for the severity of pulmo-
nary embolism. Of note, one in nine hospitalizations for pul-
monary embolism were recorded in women before
13 weeks of gestation, a time when clinicians may not be
thinking of pulmonary embolism as the most likely diagnosis
in a symptomatic woman.
Our study has limitations. First, because our results are
based on administrative data and the original charts could
not be directly verified, we cannot exclude code misclassifica-
tion or missed diagnoses of other complications that can
manifest during pregnancy or delivery, including amniotic
fluid embolism. Fatal pulmonary embolism events occurring
out of hospital or diagnosed post-mortem are not captured
in the German Inpatient Registry, possibly leading to an un-
derestimation of real estimates. Second, we estimated the in-
cidence of pulmonary embolism events during pregnancy
based on the number of (live) births in Germany in the same
year; however, this figure did not include pregnancies
interrupted by miscarriages until the 20th week. Third, we
were able to study the association between variables or
events registered during hospitalization, but we had no infor-
mation on their temporal/causal relationship. In light of this
issue and the relatively small number of deaths recorded,
we could not further investigate the potential influence of
specific patient characteristics or factors on the outcomes,
including caesarean section. With this respect, it would be
impossible to distinguish whether it represented an under-
lying cause of pulmonary embolism or, conversely, was
attempted as a last resort option after its diagnosis. Finally,
due to German legal regulations, we were not allowed to
show the results of analyses for complications or proce-
dures involving fewer than five patients: therefore, we
could not analyse the rate of major bleeding complications
in women undergoing systemic thrombolysis. For the
same reason, we were not allowed to identify individual
patients, and we cannot exclude that some had repeated
hospitalizations.
The case fatality rate of acute pulmonary embolism re-
mains substantial among pregnant women in a high-income
country like Germany. Systemic thrombolysis was used in
a minority of pregnant women with pulmonary embolism
and haemodynamic failure. Our findings may partly explain
the discrepancy between women and men in age-specific
mortality rate and proportionate mortality related to pul-
monary embolism previously described in Western Euro-
pean countries. Better preventive and management
strategies should be urgently implemented in this vulnera-
ble patient group.
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